
Opinion|Videos|March 6, 2025
Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer
Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Could you walk through the ADC therapies that are approved for HR+ HER2-negative/low and triple-negative BC?
- What key differences in the safety of T-DXd, SG, and Dato-DXd are important for pharmacists to understand?
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists as the Glue in Cardio-Kidney-Metabolic Care
2
Building a CDTM Program Means Starting Small
3
Extended-Interval Tarlatamab Dosing Offers Pharmacists More Flexible Administration Windows in SCLC
4
Pharmacists Weigh Health, Not Just Weight, in Obesity Care
5



































































































